Navidea Biopharma (NAVB) Announces Data on Ability of Novel Manocept Immunotherapy to Kill Activated Macrophages from KS Patients
Tweet Send to a Friend
Macrophage Therapeutics, a newly created business unit of Navidea Biopharmaceuticals, Inc. (NYSE: NAVB), hosted a conference where data was presented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
